Fundraising Fox

K36 Therapeutics

Founded 2021 · 14 employees on LinkedIn · 3 known investors

K36 Therapeutics develops small-molecule inhibitors targeting the histone methyltransferase NSD2 for hematologic and solid tumor cancers. Its clinical pipeline includes gintemetostat (KTX-1001) for multiple myeloma and KTX-2001 for metastatic castration-resistant prostate cancer.

BiotechHealthtech

Investors · 3

Atlas VentureCambridge · $500K – $1M
F-Prime CapitalCambridge · $3M – $10M
Nextech InvestZurich · $648K – $3.2M

In the news

K36 Therapeutics Raises $70M in Series B Financing | Precision Medicine Onlineprecisionmedicineonline.com · Jun 2023K36 Therapeutics raises $70M in Series B to fund multiple myeloma researchendpoints.news · Jun 2023K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)prnewswire.com · Jun 2023K36 Therapeutics Raises $70 Million to Fund Clinical Proof of Concept of Rare Cancer Treatment - Global Genesglobalgenes.org · Jun 2023K36 Therapeutics Launches with $30 Million to Target Multiple Myeloma - Global Genesglobalgenes.org · Dec 2021K36 emerges with $30M to bankroll multiple myeloma drug in-licensed from Novartis | Fierce Biotechfiercebiotech.com · Dec 2021

Frequently asked questions

What does K36 Therapeutics do?
K36 Therapeutics develops small-molecule inhibitors targeting the histone methyltransferase NSD2 for hematologic and solid tumor cancers. Its clinical pipeline includes gintemetostat (KTX-1001) for multiple myeloma and KTX-2001 for metastatic castration-resistant prostate cancer.
Who are K36 Therapeutics's investors?
K36 Therapeutics's investors include Atlas Venture, F-Prime Capital, Nextech Invest.